Online inquiry

IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4739MR)

This product GTTS-WQ4739MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SOST gene. The antibody can be applied in Osteogenesis imperfecta (OI) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_025237.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50964
UniProt ID Q9BQB4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4739MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14761MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ8678MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ188MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ6052MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ11139MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ13747MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ7227MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ1738MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ADC-1013
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW